PRPatricia Ribaud

Patricia Ribaud

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Patricia Ribaud has a total of 115 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Aspergilloses pulmonaires invasives survenant sous traitement par posaconazole (PZA)

    by M. Patout, C. Fercocq, A. Alanio, S. Touratier, E. Raffoux, F. Derouin, J.M. Molina, S. Bretagne, P. Ribaud, A. Bergeron

  • Open Access

    Breakthrough Disseminated Aspergillus ustus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients Receiving Voriconazole or Caspofungin Prophylaxis

    by Juliette Pavie, Claire Lacroix, Dea Garcia Hermoso, Marie Robin, ChristèlE Ferry, Anne Bergeron, Martine Feuilhade, FrançoIse Dromer, Eliane Gluckman, Jean-Michel Molina, et al.

    Aspergillus ustus is an uncommon clinical species which is poorly susceptible to antifungals. We report two cases of A. ustus infections that occurred in allogeneic stem cell transplant recipients while they were receiving either voriconazole or caspofungin. Prolonged use of these new antifungal agents may increase the risk of the emergence of resistant organisms.


  • Open Access

    Invasive Aspergillosis in Allogeneic Stem Cell Transplant Recipients: Increasing Antigenemia Is Associated with Progressive Disease

    by Francois Boutboul, Corinne Alberti, Thierry Leblanc, Annie Sulahian, Eliane Gluckman, Francis Derouin, Patricia Ribaud

    The kinetics of serum Aspergillus galactomannan, as determined by enzyme-linked immunosorbent assay, was examined in 37 allogeneic stem cell transpla


  • Influence of CD34+ marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia

    by R Morariu-Zamfir, V Rocha, A Devergie, G Socié, P Ribaud, H Esperou, N Parquet, P Guardiola, L Dal Cortivo, H Bittencourt, et al.

    In order to study the influence of bone marrow CD34+ cell dose on the outcome of allogeneic bone marrow transplantation (BMT), we analysed the results of BMT from HLA-identical siblings donors in 50 patients with chronic myeloid leukaemia (CML). The median numbers of nucleated cells (NC) and CD34+ cells infused were 2.18 × 108/kg (0.05–4.14 × 108/kg) and 3.12 × 106/kg (0.35–8.52 × 106/kg), respectively. All patients engrafted. In univariate analysis, there was no correlation between the number of CD34+ cells infused and the time to neutrophil recovery (P = 0.17). The Kaplan–Meier estimate of grade II–IV acute graft-versus-host disease (GVHD) at day 100 was 53 ± 14% and 2-year survival was 46 ± 15%. A number of CD34+ cells infused greater than the median was the main factor increasing survival (P = 0.0006) and decreasing 100 day transplant-related mortality (P = 0.009). Patient-, disease- and transplant-related characteristics were not statistically different among patients receiving more or less than the median number of CD34+ cells. The rate of infectious deaths was significantly higher in patients receiving less than 3.12 × 106 CD34/kg (48% vs 16%, P = 0.01). In a multivariable analysis, two factors associated with increased risk of death were advanced disease status at transplant (HR: 2.5 (95% CI: 1.09–5.75), P = 0.03) and a lower number of marrow CD34+ cells infused/kg (HR: 4.55 (95% CI: 1.87–10.90), P = 0.0008). Bone Marrow Transplantation (2001) 27, 575–580.


  • Open Access

    Resistant Herpes Simplex Virus Type 1 Infection: An Emerging Concern after Allogeneic Stem Cell Transplantation

    by Yolande Chen, Catherine Scieux, Valérie Garrait, Gérard Socié, Vanderson Rocha, Jean‐Michel Molina, Danielle Thouvenot, Florence Morfin, Laurent Hocqueloux, Laurent Garderet, et al.

    Fourteen cases of severe acyclovir-resistant herpes simplex virus type 1 (HSV-1) infection, 7 of which showed resistance to foscarnet, were diagnosed


  • Hepatic veno-occlusive disease

    by Patricia Ribaud, Eliane Gluckman

    Hepatic veno-occlusive disease (VOD) after stem cell transplantation is a toxic manifestation of the conditioning regimen most probably emphasized by the allogeneic reaction. Its overall mortality rate is < 4% in adults as well as in children. Recent progress has been achieved in the diagnosis of this complication. However, better methods of both prophylaxis and treatment are needed.


    • 18 September 1999
      • Vol. 28  (27) , 1488-94

    [Bone marrow transplantation in the treatment of autoimmune diseases. ISAMAIR Group].

    by D Farge, M Breban, L Guillevin, J C Piette, J Cabane, P Cherin, J Cosserat, D Sicard, P Ribaud, J P Marolleau, et al.

    EXPERIMENTAL BASIS AND CLINICAL OBSERVATIONS: Remission of an autoimmune disease has been observed in certain patients after bone marrow allograft from a healthy donor. Autoimmune disease in the donor can also be transmitted to an unaffected recipient. These phenomena would be hematopoietic-dependent. BONE MARROW ALLOGRAFTS: Indications for the treatment of refractory autoimmune diseases are exceptional due to the related mortality even in patients without malignant hematologic disease. A NEW THERAPEUTIC CONCEPT: Therapeutic intensification, followed with autologous peripheral stem cell grafts, a procedure with a mortality below 3% in 1997, constitutes a therapeutic alternative in these difficult indication concerning severe refractory autoimmune diseases including: sclerodermia, vasculitis, lupus, inflammatory myositis, autoimmune cyopenia.

    • 1 May 1999
      • Vol. 105  (2) , 366-8

    Bone marrow transplantation for paroxysmal nocturnal haemoglobinuria.

    by M Bemba, P Guardiola, L Garderet, A Devergie, P Ribaud, H Esperou, M H Noguera, E Gluckman, G Socié

    Paroxysmal nocturnal haemoglobinuria (PNH) is an acquired clonal disorder of the haemopoietic stem cells for which the only curative treatment is bone marrow transplantation. There are few reports on the use of allogeneic transplantation for PNH, and nearly all of them include only a few patients. Between September 1978 and December 1997, 16 patients underwent marrow transplantation for PNH at the Hospital Saint Louis. The 5-year survival rate for the 16 patients was 58 +/- 13%. Two factors, an absolute neutrophil count >1.0 x 109/l and haemoglobin level >9 g/dl at transplant, were found to be statistically associated with a better outcome.


  • Open Access

    Survival and Prognostic Factors of Invasive Aspergillosis After Allogeneic Bone Marrow Transplantation

    by Patricia Ribaud, Claude Chastang, Jean-Paul Latgé, Laurence Baffroy-Lafitte, Nathalie Natquet, Agnès Devergie, Hélène Espérou, Fadhéla Sélimi, Vanderson Rocha, Francis Derouin, et al.

    To determine prognostic factors for survival in bone marrow transplant recipients with invasive aspergillosis (IA), we retrospectively reviewed 27 IA


    • 1 January 1997
      • Vol. 148  (2) , 132-5

    [Veno-occlusive disease after bone marrow transplantation: preventive effect of heparin].

    by N Parquet, A Devergie, G Socié, P Ribaud, H Espérou, E Gluckman

    Liver veno-occlusive disease is a severe toxic effect observed after bone marrow transplantation. Clinical manifestations are jaundice, painful liver enlargement, and fluid-sodium retention. Histologically there is non-thrombotic obliteration of the centro-lobular veins associated with centro-lobular necrosis. This severe complication of bone marrow transplantation occurs early and is caused by a toxic processing effect. Incidence is variable, 2 to 50% in reported series, depending on patients, type of marrow provessing and on diagnostic criteria (which hinders comparison between studies). According to most studies, veno-occlusive disease regresses spontaneously. Mortality, depending on the severity of the symptoms, varies from 20 to 50%. Pathogenesis remains under debate: the initial event would occur in the sinusoid endothelium creating a state of local hypercoagulability by release of tissue factors favoring deposit of coagulation factors, especially factor VIII, in the subendothelial region of the veinules. There is also a direct toxic effect on centro-lobular hepatocytes which is further aggravated by ischemia and venous stasis. use of heparin to prevent veno-occlusive disease was proposed by the Besançon group in 1985 after they observed a low incidence (1 case in 65) in patients who were given low doses of heparin to maintain patent central catheters. The same team confirmed in 1992 the low incidence in a large retrospective series of 444 patients given either an autograft (3 cases in 253 patients, i.e. 1.2%), or an allograft (5 cases in 191 patients, i.e. 2.6%). Two single-center studies, one in Seattle and the other at the Saint-Antoine hospital in Paris, published in 1990 and 1991, did not show any difference in patients given heparin or not. Inversely, a randomized study published by Attal in 1992 including 161 patients showed a significant difference in the incidence of veno-occlusive disease between patients given heparin (2.5%) and those who were not given heparin (13.7%; p < 0.01). All these studies show that with low doses (100-150 U/kg) the risk is very very low. The mechanism of action of heparin would appear to be related to its protective effect on the endothelium rather than its hemostasis effect. The vascular protective effect of prostaglandin E1 suggests it might also be useful in preventing veno-occlusive disease.